Low cholesterol and cancer

Journal of Clinical Oncology

Volumn 14, Issue 11, 1996, Pages 3043-3048

  Kritz, H ^a   Zielinski, C ^a   Sinzinger, H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ANTIOXIDANT; APOLIPOPROTEIN B; CARMUSTINE; CHOLESTEROL; CLOFIBRATE; COMPACTIN; FLUINDOSTATIN; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMORAL ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INSULIN; INTERLEUKIN 2; LIOTHYRONINE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MEVALONIC ACID; MEVINOLIN; PLATELET DERIVED GROWTH FACTOR; PYROPHOSPHATE; RAS PROTEIN; SIMVASTATIN; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN; VITAMIN;

ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; CANCER RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

EID: 0029827595     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.11.3043     Document Type: Review

References (66)

1. Törnberg SA, Holm LE, Cartensen JM, et al: Cancer incidence and cancer mortality in relation to serum cholesterol. J Natl Cancer Inst 81:1917-1921, 1989
2. Cowan LD, O'Connell DL, Criqui MH, et al: Cancer mortality and lipid and lipoprotein levels. The Lipid Research Clinics Program Mortality Follow-Up Study. Am J Epidemiol 131:468-482, 1990
3. Isles CG, Hole DJ, Gillis CR, et al: Plasma cholesterol, coronary heart disease, and cancer in the Renfrew and Paisley survey. Br Med J 298:920-924, 1989
4. Ginsberg G, Gilbert HS: Hypocholesterolemia in myeloproliferative diseases with myelotibrosis. Prog Clin Biol Res 154:345-357, 1984
5. Reverter JC, Sierra J, Marti-Tutusaus JM, et al: Hypocholesterolemia in acute myelogenous leukemia. Eur J Haematol 41:317-320, 1988
6. Bjelke E: Colon cancer and blood cholesterol. Lancet 1:1116-1117, 1974
7. Kark JD, Smith AH, Hames CG: The relationship of serum cholesterol to the incidence of cancer in Evans County, Georgia. J Chronic Dis 33:311-322, 1980
8. Lilienfeld AM: The human fog: Cancer and cholesterol. Am J Epidemiol 114:1-4, 1981
9. Feinleib M: Review of the epidemiological evidence for a possible relationship between hypocholesterolemia and cancer. Cancer Res 43:2503-2507, 1983 (suppl 5)
10. Buddy BS: Dietary fat and its relationship to large bowel cancer. Cancer Res 41:3700-3705, 1981
11. Bases RE, Krakoff IH: Studies of serum cholesterol levels in leukemia. J Reticuloendothel Soc 2:8-14, 1965
12. Budd D, Ginsberg H: Hypocholesterolemia and acute myelogeneous leukemia: Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 58:1361-1365, 1986
13. Gilbert HS, Ginsberg H, Fagerstrom R, et al: Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity. Am J Med 71:595-602, 1981
14. Miller SR, Tartter PI, Papatestas AE, et al: Serum cholesterol and human colon cancer. J Natl Cancer Inst 67:297-300, 1981
15. Vitols S, Gahrton G, Ost A, et al: Elevated low-density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 5:1186-1193, 1984
16. Peterson C, Vitols S, Rudling M, et al: Hypocholesterolemia in cancer patients may be caused by elevated KDK-receptor activities in malignant cells. Med Oncol Tumor Pharmacother 2:143-147, 1985
17. Kritchevsky SB, Kritchevsky D: Serum cholesterol and cancer risk: An epidemiologic perspective. Annu Rev Nutr 12:391-416, 1992
18. Linton MF, Farese RV, Young SG: Familial hypobetalipoproteinemia. J Lipid Res 34:521-541, 1993
19. Xing-sheng Y, Kesteloot H, Da-xian H: Serum cholesterol in China and the West. Chin Med J 99:183-186, 1986
20. Dunnigan MG: The problem with cholesterol. No light at the end of this tunnel? Br Med J 306:1355-1356, 1993
21. Oliver MF, Heady JA, Morris JN, et al: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. Br Heart J 40:1069-1118, 1978
22. Shepherd J: Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Fur Heart J 16:5-13, 1995
23. Frick MH, Elo O, Haapa K, et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, change in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
24. Lipid Research Clinics Coronary Primary Prevention Trial: I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251:351-374, 1984
25. Henry PD: The cholesterol pessimist. J Am Coll Cardiol 23:818-819, 1988
26. Canner PL, Berge KG, Wenger NK, et al: Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 9:1245-1255, 1986
27. Multiple Risk Factor Intervention Trial Research Group: Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: Findings related to a priori hypothesis of the trial. JAMA 263:1795-1801, 1990
28. Muldoon MF, Manuck SB, Matthews KA: Lowering cholesterol concentrations and mortality: A quantitative review of primary prevention trials. Br Med J 301:309-314, 1990
29. Jacobs D, Blackburn H, Higgins M, et al: Report of the Conference on Low Blood Cholesterol: Mortality associations. Circulation 86:1046-1060, 1992
30. Knekt P, Reunanen A, Aromaa A, et al: Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol 41:519-530, 1988
31. Marini A, Carulli G, Azzara A, et al: Serum cholesterol and triglycerides in hematological malignancies. Acta Haematol 81:75-79, 1989
32. Verdery RB, Goldberg AP: Hypocholesterolemia as a predictor of death: A prospective study of 224 nursing home residents. J Gerontol 46:M84-90, 1991
33. Noel MA, Smith TK, Ettinger WH: Characteristics and out-comes of hospitalized older patients who develop hypocholesterolemia. J Am Geriatr Soc 39:455-461, 1991
34. Ho YK, Smith RG, Brown MS, et al: Low-density lipoprotein(LDL) receptor activity in human acute myelogenous leukemia cells. Blood 52:1099-1114, 1978
35. Ueyama Y, Matsuzawa Y, Yamashita S, et al: Hypocholesterolaemic factor from gallbladder cancer cells. Lancet 2:707-709, 1990
36. Blau L, Bittman R: Cholesterol distribution between the two halves of the lipid bilayer of human erythrocyte ghost membranes. J Biol Chem 253:8366-8368, 1978
37. Reinhart MP, Billheimer JT, Faust JR, et al: Subcellular localization of the enzymes of cholesterol biosynthesis and metabolism in rat liver. J Biol Chem 262:9649-9655, 1987
38. 99mtechnetium-LDL imaging in patients with myeloproliferative disease. Ann Intern Med 110:208-213, 1989
39. Klock JC, Pieprzyk JK: Cholesterol, phospholipids and fatty acids of normal immature neutrophils: Comparison with acute myeloblastic leukaemia cells and normal neutrophils. J Lipid Res 20:908-911, 1979
40. Inbar M, Shinitzky M: Cholesterol as a bioregulator in the development and inhibition of leukaemia. Proc Natl Acad Sci USA 71:4229-4231, 1974
41. Swaminathan N, Venkataraman K, Gadgil U, et al: Possible mechanism of interleukin-2-induced decline of serum cholesterol during adoptive cellular immunotherapy in cancer patients. Biochem Med Metab Biol 49:212-216, 1993
42. Leichter SB, Daughaday WH: Massive steroid excretion and hypocholesterolemia with an adrenal adenoma. Ann Intern Med 81:638-640, 1974
43. Nakagawa T, Ueyama Y, Nozaki S, et al: Marked hypocholesterolemia in a case with adrenal adenoma-Enhanced catabolism of low-density lipoprotein (LDL) via the LDL receptors of tumor cells. J Clin Endocrinol Metab 80:92-96, 1995
44. Shiroeda O, Yamaguchi N, Kawai K: Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line. Cancer Res 47:4630-4633, 1987
45. Buchwald H: Cholesterol inhibition, cancer, and chemotherapy. Lancet 2:1154-1156, 1992
46. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
47. Morris TJ, Palm SI, Pena J, et al: Inhibition of hepatoma tissue culture-4 growth by lovastatin: A novel chemotherapeutic strategy. Surg Forum 42:452-454, 1991
48. Maltese WA, Defendini R, Green RA, et al: Suppression of marine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest 76:1748-1754, 1985
49. Siperstein MD, Pagan VM: Deletion of the cholesterol-negative feedback system in liver tumors. Cancer Res 24:1108-1115, 1964
50. Quesney-Huneeus V, Wiley MH, Siperstein MD: Essential role for mevalonate synthesis in DNA replication. Proc Natl Acad Sci USA 76:5056-5060, 1979
51. Chen HW, Kandutsch AA, Heiniger HJ: The role of cholesterol in malignancy. Prog Exp Tumor Res 22:275-316, 1978
52. Quesney-Huneeus V, Galick HA, Siperstein MD, et al: The dual role of mevalonate in the cell cycle. J Biol Chem 258:378-385, 1983
53. Schaffer WA, Kin R, Sterne R, et al: Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science 245:379-385, 1989
54. Littman ML, Taguchi T, Mosbach EH: Effect of cholesterol-free, fat-free diet and hypocholesterolemic agents on growth of transplantable animal tumors. Cancer Chemother Rep 50:25-45, 1966
55. Schneider PD, Chan EK, Guzman IJ, et al: Retarding Novikoff tumor growth by altering host rat cholesterol metabolism. Surgery 87:409-416, 1980
56. Addleman W: Cancer, cholesterol and cholestyramine. N Engl J Med 287:1047, 1972
57. Corsini A, Raiteri M, Soma M, et al: Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res 23:173-180, 1991
58. Corsini A, Mazzotti M, Raiteri M, et al: Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 101:117-125, 1993
59. Soma MR, Baetta R, De Renzis MR, et al: In vivo enhanced antitumor activity of carmustine (N,N'-bis[2-chloroethyl]-N-nitrosourea) by simvastatin. Cancer Res 55:597-602, 1995
60. Soma MR, Pagliarini P, Butti G, et al: Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. Cancer Res 52:4348-4355, 1992
61. Smith SC Jr, Blair SN, Criqui MH, et al: AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. J Am Coll Cardiol 26:292-294 and 291, 1995
62. Gotto AM Jr: Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. Circulation 92:646-656, 1995
63. Yeshurun D, Gotto AM Jr: Hyperlipidemia: Perspectives in diagnosis and treatment. South Med J 88:379-391, 1995
64. Kramer LM: Implementing new dietary guidelines of the National Cholesterol Education Program. AACN Clin Issues 6:418-431, 1995
65. Summary of the Second Report of the National Cholesterol Education Program (NCEP): Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269:3015-3023, 1993
66. Rossouw JE, Gotto AM Jr: Does low cholesterol cause death? Cardiovasc Drugs Ther 7:789-793, 1993